Drugs & Side Effects |

Cancer Drugs News

Merck CEO Comments on New Cervical Cancer Vaccine

RSS News Feeds
Drugs & Pharmacuticals
Cancer Drugs
Fosamax
 All RSS Feeds

At a glance:

Merck is optimistic about its new cervical cancer vaccine, Gardasil. The vaccine was approved by the FDA last week. It is the first of its kind, although GlaxoSmithKline has one in development. 
 
The vaccine protects against 70% of the viruses that cause cervical cancer, and is intended for females between the ages of 9 and 26 and males between 9 and 24.  
 
Merck's CEO stated, at a health care conference, that Merck is reducing costs by outsourcing drug manufacturing to countries such as India, where they use facilities that are FDA approved but much cheaper to operate.

Merck CEO optimistic about outlook for Gardasil

MarketWatch - 6/15/2006 12:01 AM

While Merck & Co. (MRK) just got approval for its new cervical cancer vaccine Gardasil last week, Chief Executive Richard Clark is optimistic about the outlook for the drug based on its target demographic population.
 

 
The vaccine protects against four strains of the human papillomavirus, or HPV, two of which account for about 70% of cervical cancer cases. There are more than 100 strains of HPV.
 
· Read The Full Cancer Drugs Article From MarketWatch -->

· Read All Cancer Drugs News Stories -->

Comments On Cancer Drugs News Articles:


No Current Comments
Posted by Admin on 3/20/2006

There are no current comments. Why not post one?

Leave a Comment:

Once you click the 'Save Comment' button, you will receive a verification email from our website. Be sure to change any spam settings to allow webmaster@lawsuitsearch.com as a trusted sender.
 
If you are already a member, you can Sign In Here.
 
You can create your own FREE user account that you can use to participate in our message boards, blogs, newsletters and other community activities such as this one. To get your FREE user account, click here.

Email Address:

Your Name:

Message Title:

Message: